$42.57
4.34%
NYSE, Nov 16, 04:19 pm EST. Closed.
ISIN
US8816242098
Symbol
TEVA

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$42.57
+1.07 2.58% 1M
+13.38 45.84% 6M
+13.96 48.79% YTD
+16.57 63.73% 1Y
+33.90 391.03% 3Y
+33.18 353.45% 5Y
-8.49 16.63% 10Y
+4.22 11.00% 20Y
NYSE, Closing price Mon, Nov 16 2026
-1.93 4.34%
ISIN
US8816242098
Symbol
TEVA
Industry

AI Insights on Teva Pharmaceutical Industries Limited Sponsored ADR Insights AI Insights on Teva Pharmaceutical Industries Limited Sponsored ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Teva Pharmaceutical Industries Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$50.5b
Enterprise Value
$63.1b
Net debt
$12.6b
Cash
$4.1b
Shares outstanding
1.2b
Valuation
P/E
99.0
P/S | estimate
2.9 | 3.0
EV/Sales | estimate
3.7 | 3.7
EV/FCF | ex SBC
51.1 | 59.4
P/B
6.3
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
$17.2b | $17.0b
EBITDA
$4.4b
EBIT
$3.4b
Net Income
$506.0m
Free Cash Flow | ex SBC
$1.2b | $1.1b
Growth
Revenue | estimate
2.7% | -1.4%
EBITDA
-8.5%
EBIT
-10.0%
Net Income
-28.9%
Free Cash Flow
113.7%
Margin
Gross
53.6%
EBITDA
25.7%
EBIT
19.9%
Net
2.9%
Free Cash Flow | ex SBC
7.2% | 6.2%
Financial Health
Equity Ratio
19.4%
Return on Equity
17.8%
ROCE
14.0%
ROIC
16.8%
Debt/Equity
2.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$172.0m | 1.0%
SBC as % of FCF
13.9%
SBC Growth 1Y
22.9%
Share Count Growth 1Y
1.7%
Shareholder Yield
-1.7%
More
EPS
$0.4
FCF per Share
$1.1
Short interest
2.4%
Employees
-
Rev per Employee
-

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy
86%
Hold
14%

Teva Pharmaceutical Industries Limited Sponsored ADR Events

Past Events
NOV
11
Special Call - Teva Pharmaceutical Industries Limited
6 days ago
NOV
3
Q3 2026 Earnings Call
14 days ago
OCT
9
Special Call - Teva Pharmaceutical Industries Limited
about one month ago
SEP
23
Bank of America Global Healthcare Conference 2026
about 2 months ago
SEP
22
U.S. All Stars Conference
about 2 months ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
2
Special Call - Teva Pharmaceutical Industries Limited
3 months ago
JUL
29
Q2 2026 Earnings Call
4 months ago
JUL
7
Special Call - Teva Pharmaceutical Industries Limited
4 months ago
JUN
8
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
APR
29
Q1 2026 Earnings Call
7 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
9
Leerink Global Healthcare Conference 2026
8 months ago
FEB
17
Special Call - Teva Pharmaceutical Industries Limited
9 months ago
JAN
28
Q4 2025 Earnings Call
10 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
4
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
18
Jefferies London Healthcare Conference 2025
12 months ago
NOV
10
UBS Global Healthcare Conference 2025
about one year ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Sep '26
+/-
%
17,230 17,230
3% 3%
100%
- Direct Costs 7,992 7,992
2% 2%
46%
9,238 9,238
7% 7%
54%
- Selling and Administrative Expenses 4,161 4,161
9% 9%
24%
- Research and Development Expense 1,756 1,756
77% 77%
10%
4,420 4,420
8% 8%
26%
- Depreciation and Amortization 985 985
3% 3%
6%
EBIT (Operating Income) EBIT 3,435 3,435
10% 10%
20%
Net Profit 506 506
29% 29%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Teva Pharmaceutical Industries Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
●
6 days ago
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
Positive
Reuters
●
14 days ago
Teva Pharmaceutical Industries expects to grow in ​2027 despite the US ‌inflation reduction act that will cap prices for its top ​branded drug Austedo to ​treat Huntington's Disease and Tardive ⁠Dyskinesia, CEO Richard Francis ​said on Tuesday.
More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office Israel
CEO Mr. Francis
Founded 1901
Website www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today